This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Accurin Kinase Inhibitor (Pfizer)
Drug Names(s): Accurin
The specific kinase target(s) have not been released by the companies, but this compound was developed using one of Pfizer's proprietary kinase inhibitors and one of BIND's proprietary ligands.
BioMedTracker will update the drug and target when more information is released from the companies.
BIND Therapeutics and Pfizer
In April 2013, BIND Therapeutics announced that it has entered into a global collaboration agreement with Pfizer to develop and commercialize Accurins utilizing select small molecule targeted therapies. The collaboration aims to employ BINDs Medicinal Nanoengineering platform to impart tissue and cellular targeting capabilities to molecularly targeted drugs.
Under the terms of the agreement, Pfizer will have the exclusive option to pursue development and commercialization of the Accurins selected by its team. Both companies will work together on preclinical research, and if Pfizer exercises its option, Pfizer will have responsibility for development and commercialization of the selected Accurins. BIND could receive up-front and development milestone payments totaling approximately $50 million and approximately $160 million in regulatory and sales milestone payments for each Accurin commercialized as well as tiered royalties on potential...See full deal structure in Biomedtracker
Accurin Kinase Inhibitor (Pfizer) News
Additional information available to subscribers only: